Skip to main content
NEW IDENTITY. SAME PURPOSE. Janssen is now J&J Innovative Medicine.  
 
VISIT JANSSEN GLOBAL
 
 
 

UK
change location▼

Search
Search

Welcome to Janssen UK

Visit Janssen Global

Media Centre

The News Centre is intended to provide resources for media professionals only. It is not intended for use by healthcare professionals, patients or the general public. To access, please confirm that you are an accredited member of the press. I hereby confirm that I am an accredited member of the press
I Agree Cancel

Press Releases

14, September, 2024

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

11, September, 2024

RYBREVANT®▼ (amivantamab) plus lazertinib shows favourable overall survival trend in EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib

09, September, 2024

SMC accepts bispecific antibody TECVAYLI®▼ (teclistamab) for eligible patients with relapsed and refractory multiple myeloma

19, July, 2024

NICE issues draft guidance on bispecific antibody TECVAYLI®▼ (teclistamab) for eligible patients with relapsed and refractory multiple myeloma after three treatments

12, June, 2024

Johnson & Johnson Disheartened That NICE Will Not Re-Appraise Guidance for SPRAVATO®▼ (esketamine) Nasal Spray for Treatment-Resistant Major Depressive Disorder

21, May, 2024

Data from the Phase 3 QUASAR Maintenance Study demonstrates guselkumab achieves the primary endpoint and all nine major secondary endpoints, including endoscopic normalisation and histo-endoscopic mucosal improvement

View more Press Releases

Quick Links

 

FOLLOW US

 

Twitter

Follow us on Twitter